Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. Sweden
  4. Nasdaq Stockholm
  5. Karolinska Development AB (publ)
  6. News
  7. Summary
    KDEV   SE0002190926

KAROLINSKA DEVELOPMENT AB (PUBL)

(KDEV)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsOther languagesPress ReleasesOfficial PublicationsSector news

Karolinska Development's portfolio company Modus Therapeutics initiates Phase 1b trial of its drug candidate sevuparin

12/01/2021 | 06:00am EST

STOCKHOLM SWEDENDecember 1, 2021. Karolinska Development AB (Nasdaq Stockholm: KDEV) announces today that its portfolio company Modus Therapeutics has dosed the first subject in a phase 1b study of sevuparin. The drug candidate is being developed as a potential treatment for sepsis/septic shock, a serious and often fatal condition.

The randomized, placebo-controlled Phase 1b study will evaluate the effect of sevuparin on symptoms in healthy individuals injected with the bacterial toxin lipopolysaccharide (LPS) in the skin (local inflammation) and in the blood (systemic inflammation). Provocation with LPS is a well-established experimental model to characterize the early stages of septic inflammation by eliciting measurable symptoms. In addition, the study will evaluate the safety profile of sevuparin when used in combination with standard prophylactic blood-thinning heparin therapy.

“We are pleased that our portfolio company Modus Therapeutics has made further progress in the development of sevuparin as a potential treatment for sepsis/septic shock, and we look forward to the results of the important Phase 1b study that is now in progress,” comments Karolinska Development's CEO Viktor Drvota.

Karolinska Development's direct ownership interest, and indirect ownership interest via KDev Investment, in Modus Therapeutics amounts to 38% and 17%, respectively.

For further information, please contact:

Viktor Drvota, CEO, Karolinska Development AB
Phone: +46 73 982 52 02, e-mail: viktor.drvota@karolinskadevelopment.com

Johan Dighed, General Counsel and Deputy CEO, Karolinska Development AB
Phone: +46 70 207 48 26, e-mail: johan.dighed@karolinskadevelopment.com

TO THE EDITORS

About Karolinska Development AB

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations in the Nordic region that are developed by entrepreneurs and leadership teams. The Company invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has a portfolio of ten companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit www.karolinskadevelopment.com.

Attachment

  • KD PR Modus 2021-12-01 eng

© OMX, source GlobeNewswire - EU Press Releases

All news about KAROLINSKA DEVELOPMENT AB (PUBL)
01/14Karolinska Development AB publishes prospectus including previously unpublished financi..
AQ
01/13KAROLINSKA DEVELOPMENT AB (PUBL) : RIGHTS ISSUE: 7 new shares @ 4 SEK for 10 existing shar..
FA
01/12Karolinska Development's Extraordinary General Meeting 2022
AQ
01/12Karolinska Development AB Announces Executive Changes
CI
01/11Karolinska Development's portfolio company Umecrine Cognition presents preclinical data..
AQ
01/11Karolinska Development's portfolio company Svenska Vaccinfabriken appoints Richard Beth..
AQ
2021Organon's acquisition of Karolinska Development's portfolio company Forendo Pharma has ..
AQ
2021ORGANON & CO. COMPLETED THE ACQUISIT : KDEV), KD Co-Investment Fund KB, fund managed by Ka..
CI
2021Notice of Extraordinary General Meeting in Karolinska Development AB (publ)
AQ
2021Karolinska Development AB (publ) proposes a rights issue of approximately SEK 491 milli..
AQ
More news
Financials
Sales 2021 2,00 M 0,22 M 0,22 M
Net income 2021 189 M 20,3 M 20,3 M
Net Debt 2021 - - -
P/E ratio 2021 -
Yield 2021 -
Capitalization 772 M 83,0 M 83,1 M
Capi. / Sales 2021 386x
Capi. / Sales 2022 386x
Nbr of Employees 7
Free-Float 91,7%
Chart KAROLINSKA DEVELOPMENT AB (PUBL)
Duration : Period :
Karolinska Development AB (publ) Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends KAROLINSKA DEVELOPMENT AB (PUBL)
Short TermMid-TermLong Term
TrendsBearishNeutralBullish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 0
Last Close Price 4,40 SEK
Average target price 7,90 SEK
Spread / Average Target 79,5%
EPS Revisions
Managers and Directors
Richard Bethell Chief Executive Officer
Per Gunnar Ernst Aniansson Chief Financial Officer & Investment Director
Bj÷rn Cochlovius Director
John Íhd Chief Scientific Officer & Venture Partner
Vladimir Valeryevich Artamonov Independent Director
Sector and Competitors
1st jan.Capi. (M$)
KAROLINSKA DEVELOPMENT AB (PUBL)-6.60%84
ABBOTT LABORATORIES-10.59%215 794
MEDTRONIC PLC2.08%141 985
BECTON, DICKINSON AND COMPANY5.23%75 431
HOYA CORPORATION-11.34%49 186
BAXTER INTERNATIONAL INC.0.51%43 200